Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sandy

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Plos One|December 24, 2010
A transient transgenic RNAi strategy for rapid characterization of gene function during embryonic developmentBryan C Bjork, Yuko Fujiwara, Shannon W Davis, et al.
British Journal of Clinical Pharmacology|April 27, 2025
A novel approach for first-in-human dose selection using population dose-response modelling to find a minimum anticipated biological effect levelLin Yuan, Meghana Kulkarni, Evan Chiswick, et al.
Cell|June 25, 2013
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stabilityBryan King, Thomas Trimarchi, Linsey Reavie, et al.
Chemistry & Biology|November 5, 2013
Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growthShivani Garapaty-Rao, Christopher Nasveschuk, Alexandre Gagnon, et al.
Elife|January 6, 2016
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myelomaAndrew R Conery, Richard C Centore, Adrianne Neiss, et al.
Elife|July 15, 2016
Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myelomaAndrew R Conery, Richard C Centore, Adrianne Neiss, et al.
Cell|June 4, 2009
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cellsClaudia Scholl, Stefan Fröhling, Ian F Dunn, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 23, 2014
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitorsMichele Ceribelli, Priscilla N Kelly, Arthur L Shaffer, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2016
Identification of potent, selective KDM5 inhibitorsVictor S Gehling, Steven F Bellon, Jean-Christophe Harmange, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2015
Development of methyl isoxazoleazepines as inhibitors of BETMichael C Hewitt, Yves Leblanc, Victor S Gehling, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Plos One|December 24, 2010
A transient transgenic RNAi strategy for rapid characterization of gene function during embryonic developmentBryan C Bjork, Yuko Fujiwara, Shannon W Davis, et al.
British Journal of Clinical Pharmacology|April 27, 2025
A novel approach for first-in-human dose selection using population dose-response modelling to find a minimum anticipated biological effect levelLin Yuan, Meghana Kulkarni, Evan Chiswick, et al.
Cell|June 25, 2013
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stabilityBryan King, Thomas Trimarchi, Linsey Reavie, et al.
Chemistry & Biology|November 5, 2013
Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growthShivani Garapaty-Rao, Christopher Nasveschuk, Alexandre Gagnon, et al.
Elife|January 6, 2016
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myelomaAndrew R Conery, Richard C Centore, Adrianne Neiss, et al.
Elife|July 15, 2016
Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myelomaAndrew R Conery, Richard C Centore, Adrianne Neiss, et al.
Cell|June 4, 2009
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cellsClaudia Scholl, Stefan Fröhling, Ian F Dunn, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 23, 2014
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitorsMichele Ceribelli, Priscilla N Kelly, Arthur L Shaffer, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2016
Identification of potent, selective KDM5 inhibitorsVictor S Gehling, Steven F Bellon, Jean-Christophe Harmange, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2015
Development of methyl isoxazoleazepines as inhibitors of BETMichael C Hewitt, Yves Leblanc, Victor S Gehling, et al.
Pageof 3